Search
Now showing items 51-60 of 169
Developing biomarker-driven treatments for oesophagogastric cancer
(Institute of Cancer Research (University Of London), 2020-08-31)
Introduction Despite recent advances in both genetic characterisation and development of novel targeted agents the outlook for advanced oesophagogastric (OG) cancers remain poor and there is a need for improved biomarker-driven ...
Amino acid dependence in acute myeloid leukaemia
(Institute of Cancer Research (University Of London), 2022-05-31)
Acute myeloid leukaemia (AML) is a heterogeneous disease which remains curable in only a minority of patients. Outcome is dismal in the subgroup with adverse genetic features. Amino acid (AA) depletion is a therapeutic ...
Using inducible degradation to characterise the roles of TRIP13 and CEP57 in mitosis
(Institute of Cancer Research (University Of London), 2021-05-31)
DNA and centrosomes are both semi-conservatively replicated once per cell cycle and it is essential that the DNA and centrosomes are divided equally between daughter cells in mitosis. When this fails, it can lead to ...
Deciphering genetic susceptibility to multiple myeloma
(Institute of Cancer Research (University Of London), 2020-09-30)
Multiple myeloma (MM) is a malignancy characterised by the clonal expansion of plasma cells primarily from the bone marrow. The two- to four-fold increased risk observed in relatives of MM patients provides support for ...
Three-dimensional dose verification of adaptive radiotherapy at an MR-linac
(Institute of Cancer Research (University Of London), 2020-04-30)
The vision of accurate real-time image-guided radiotherapy (RT) has led to the development of MR-Linacs consisting of MRI scanners integrated within RT treatment units. The safe clinical operation of these devices requires ...
Investigating a range of late effects of Hodgkin lymphoma treatments
(Institute of Cancer Research (University Of London), 2021-01-31)
Dramatic improvement in Hodgkin lymphoma (HL) survival rates over recent decades has come at significant cost: treatment-related late effects which are epitomised in female HL patients treated at young ages. The aims of ...
Predictors of toxicity in prostate hypofractionation clinical trials
(Institute of Cancer Research (University Of London), 2021-06-30)
The effects of oncolytic Maraba virus (MG1) in malignant melanoma
(Institute of Cancer Research (University Of London), 2022-07-31)
Despite recent advances in the targeted and immunological treatment of melanoma, the incidence of this malignancy is increasing and is responsible for approximately 60,000 global deaths annually, highlighting the ongoing ...
Selective autophagy receptors in pancreatic ductal adenocarcinoma
(Institute of Cancer Research (University Of London), 2022-07-06)
Pancreatic cancer accounted for 2.5% of all new cancers diagnosed worldwide in 2018, but remains disproportionally one of the most lethal cancers. Therefore, the development and validation of novel biomarkers (BMs), for ...
Exploring novel approaches to metastatic heterogeneity and clonal evolution
(Institute of Cancer Research (University Of London), 2021-12-31)
Background Alternative methods are required to optimise the clinical insights that may be derived from studies of cancer evolution and heterogeneity. Profiling a single biopsy of tumour tissue underestimates potential ...